There is an appointed time for everything — including in biotech. There is a time to start a company, a time to wind it down, a time to go public, and a time to delist the stock.
For every hopeful biotech toiling for decades before finally realizing a profit, there are countless others that run out of money or bet on a product that never delivers.
That latter group includes more companies than just Theranos. STAT took a look at some of the biopharma and biotech companies that wound down their operations over the course of 2018 and what those companies’ executives are doing now.
About the Author Reprints
That’s what I love about managers and c-suite, not matter how much they fail, there will always be some sucker out there willing to value very much their failures and incompetence.
I wish it was the same for pretty much everything else in life!